Vertex Pharmaceuticals Inc (VRTX) · Insider trading
What Vertex Pharmaceuticals's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$158.10M
13 insiders, 100% under a plan
Net, 12 months
−$158.10M
bought less sold
Latest filing
2026-09-10
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Leiden Jeffrey MDirector, Executive Chairman | – | $60.94M | 17 | 2025-12-03 | 83,338 |
| Kewalramani ReshmaDirector, CEO & President | $3.90M | $27.57M | 16 | 2026-02-27 | 137,878 |
| Sachdev AmitEVP Chief Patient & Ext Af Off | – | $28.38M | 9 | 2026-02-25 | 55,570 |
| Wagner Charles F JrEVP, CO & FO | – | $13.98M | 5 | 2026-01-06 | 37,725 |
| Bozic CarmenEVP and CMO | – | $11.31M | 10 | 2026-06-26 | 15,337 |
| Tatsis OuraniaEVP, Chief Reg. & Quality Off. | – | $10.78M | 14 | 2026-07-02 | 45,321 |
| Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | – | $6.51M | 8 | 2026-02-25 | 18,432 |
| Altshuler DavidEVP, Chief Scientific Officer | – | $6.43M | 8 | 2025-05-15 | 23,281 |
| Biller JonathanEVP and Chief Legal Officer | – | $6.41M | 9 | 2026-02-25 | 13,659 |
| McKechnie DuncanEVP, Chief Commercial Officer | – | $5.66M | 5 | 2026-07-02 | 11,001 |
| Ambrose KristenSVP & Chief Accounting Officer | – | $3.34M | 8 | 2026-02-26 | 6,624 |
| Bunnage Mark E.EVP, Chief Scientific Officer | – | $3.00M | 5 | 2026-05-15 | 7,284 |
| Liu JoyEVP and Chief Legal Officer | – | $2.13M | 5 | 2026-07-01 | 19,131 |
| Sachs Bruce IDirector | $1.95M | – | 2 | 2025-08-06 | 41,634 |
| Bhatia Sangeeta N.Director | – | $572,950 | 4 | 2026-05-04 | 4,924 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | McKechnie DuncanEVP, Chief Commercial Officer | Saleplan | 1,541 | 519.00 | $799,779 | 11,001 | Form 4 |
| 2026-07-02 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 1,500 | 524.99 | $787,485 | 45,321 | Form 4 |
| 2026-07-01 | Liu JoyEVP and Chief Legal Officer | Saleplan | 828 | 502.71 | $416,244 | 19,131 | Form 4 |
| 2026-06-26 | Bozic CarmenEVP and CMO | Saleplan | 596 | 482.50 | $287,570 | 15,337 | Form 4 |
| 2026-06-18 | Bozic CarmenEVP and CMO | Saleplan | 1,020 | 462.17 | $471,413 | 15,933 | Form 4 |
| 2026-06-15 | Bozic CarmenEVP and CMO | Saleplan | 4,062 | 450.00 | $1.83M | 16,953 | Form 4 |
| 2026-06-05 | Bozic CarmenEVP and CMO | Saleplan | 1,745 | 450.00 | $785,250 | 21,015 | Form 4 |
| 2026-06-01 | Liu JoyEVP and Chief Legal Officer | Saleplan | 828 | 439.91 | $364,245 | 19,959 | Form 4 |
| 2026-05-29 | Bozic CarmenEVP and CMO | Saleplan | 1,974 | 450.00 | $888,300 | 22,760 | Form 4 |
| 2026-05-15 | Bozic CarmenEVP and CMO | Saleplan | 1,354 | 453.45 | $613,971 | 24,734 | Form 4 |
| 2026-05-15 | Bunnage Mark E.EVP, Chief Scientific Officer | Saleplan | 33 | 453.45 | $14,964 | 7,284 | Form 4 |
| 2026-05-12 | Bozic CarmenEVP and CMO | Saleplan | 6,988 | 450.00 | $3.14M | 26,088 | Form 4 |
| 2026-05-04 | Bhatia Sangeeta N.Director | Saleplan | 318 | 423.73 | $134,746 | 4,924 | Form 4 |
| 2026-05-01 | Liu JoyEVP and Chief Legal Officer | Saleplan | 1,104 | 425.02 | $469,222 | 20,729 | Form 4 |
| 2026-04-01 | Liu JoyEVP and Chief Legal Officer | Saleplan | 978 | 449.17 | $439,288 | 21,833 | Form 4 |
| 2026-03-27 | Bozic CarmenEVP and CMO | Saleplan | 2,329 | 450.95 | $1.05M | 33,076 | Form 4 |
| 2026-03-13 | Bozic CarmenEVP and CMO | Saleplan | 2,329 | 481.79 | $1.12M | 35,405 | Form 4 |
| 2026-03-11 | McKechnie DuncanEVP, Chief Commercial Officer | Saleplan | 2,633 | 498.42 | $1.31M | 12,489 | Form 4 |
| 2026-03-04 | McKechnie DuncanEVP, Chief Commercial Officer | Saleplan | 2,437 | 475.30 | $1.16M | 15,122 | Form 4 |
| 2026-03-02 | Liu JoyEVP and Chief Legal Officer | Saleplan | 892 | 495.96 | $442,396 | 22,811 | Form 4 |
| 2026-02-27 | Bozic CarmenEVP and CMO | Saleplan | 2,329 | 480.31 | $1.12M | 37,734 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 400 | 479.75 | $191,900 | 137,878 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 120 | 481.50 | $57,780 | 137,758 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 240 | 482.84 | $115,882 | 137,518 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 2,510 | 487.13 | $1.22M | 135,008 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 3,278 | 488.27 | $1.60M | 131,730 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 460 | 489.32 | $225,087 | 131,270 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 2,725 | 490.54 | $1.34M | 128,545 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 949 | 491.30 | $466,244 | 127,596 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 2,520 | 493.29 | $1.24M | 125,076 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 3,498 | 494.33 | $1.73M | 121,578 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 15,580 | 495.38 | $7.72M | 105,998 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 5,995 | 496.16 | $2.97M | 100,003 | Form 4 |
| 2026-02-27 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 1,725 | 496.95 | $857,239 | 98,278 | Form 4 |
| 2026-02-26 | Ambrose KristenSVP & Chief Accounting Officer | Saleplan | 357 | 483.36 | $172,560 | 6,624 | Form 4 |
| 2026-02-25 | Ambrose KristenSVP & Chief Accounting Officer | Saleplan | 223 | 486.35 | $108,456 | 6,981 | Form 4 |
| 2026-02-25 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Saleplan | 668 | 486.35 | $324,882 | 18,432 | Form 4 |
| 2026-02-25 | Biller JonathanEVP and Chief Legal Officer | Saleplan | 945 | 486.35 | $459,601 | 13,659 | Form 4 |
| 2026-02-25 | Bunnage Mark E.EVP, Chief Scientific Officer | Saleplan | 620 | 486.35 | $301,537 | 7,284 | Form 4 |
| 2026-02-25 | McKechnie DuncanEVP, Chief Commercial Officer | Saleplan | 2,500 | 486.35 | $1.22M | 19,969 | Form 4 |
85 more
| 2026-02-25 | McKechnie DuncanEVP, Chief Commercial Officer | Saleplan | 2,410 | 489.00 | $1.18M | 17,559 | Form 4 |
| 2026-02-25 | Sachdev AmitEVP Chief Patient & Ext Af Off | Saleplan | 1,846 | 486.35 | $897,802 | 55,570 | Form 4 |
| 2026-02-25 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 260 | 486.35 | $126,451 | 46,763 | Form 4 |
| 2026-02-19 | Sachdev AmitEVP Chief Patient & Ext Af Off | Saleplan | 920 | 463.91 | $426,797 | 116,627 | Form 4 |
| 2026-02-19 | Sachdev AmitEVP Chief Patient & Ext Af Off | Saleplan | 2,730 | 465.05 | $1.27M | 113,897 | Form 4 |
| 2026-02-19 | Sachdev AmitEVP Chief Patient & Ext Af Off | Saleplan | 1,848 | 465.80 | $860,798 | 112,049 | Form 4 |
| 2026-02-19 | Sachdev AmitEVP Chief Patient & Ext Af Off | Saleplan | 10,263 | 467.75 | $4.80M | 101,786 | Form 4 |
| 2026-02-19 | Sachdev AmitEVP Chief Patient & Ext Af Off | Saleplan | 19,662 | 468.57 | $9.21M | 82,124 | Form 4 |
| 2026-02-19 | Sachdev AmitEVP Chief Patient & Ext Af Off | Saleplan | 7,241 | 469.61 | $3.40M | 74,883 | Form 4 |
| 2026-02-19 | Sachdev AmitEVP Chief Patient & Ext Af Off | Saleplan | 11,712 | 470.54 | $5.51M | 63,171 | Form 4 |
| 2026-02-19 | Sachdev AmitEVP Chief Patient & Ext Af Off | Saleplan | 4,237 | 471.43 | $2.00M | 58,934 | Form 4 |
| 2026-02-18 | Ambrose KristenSVP & Chief Accounting Officer | Saleplan | 638 | 473.68 | $302,208 | 7,750 | Form 4 |
| 2026-02-18 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Saleplan | 817 | 473.68 | $386,997 | 20,727 | Form 4 |
| 2026-02-18 | Biller JonathanEVP and Chief Legal Officer | Saleplan | 1,244 | 473.68 | $589,258 | 15,748 | Form 4 |
| 2026-02-18 | Bunnage Mark E.EVP, Chief Scientific Officer | Saleplan | 1,182 | 473.68 | $559,890 | 8,486 | Form 4 |
| 2026-02-18 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 368 | 473.68 | $174,314 | 48,650 | Form 4 |
| 2026-02-17 | Ambrose KristenSVP & Chief Accounting Officer | Saleplan | 1,557 | 489.46 | $762,089 | 8,388 | Form 4 |
| 2026-02-17 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Saleplan | 2,031 | 489.46 | $994,093 | 21,544 | Form 4 |
| 2026-02-17 | Biller JonathanEVP and Chief Legal Officer | Saleplan | 2,476 | 489.46 | $1.21M | 16,992 | Form 4 |
| 2026-02-17 | Bunnage Mark E.EVP, Chief Scientific Officer | Saleplan | 2,437 | 489.46 | $1.19M | 9,668 | Form 4 |
| 2026-02-17 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 609 | 489.46 | $298,081 | 49,018 | Form 4 |
| 2026-02-13 | Bhatia Sangeeta N.Director | Saleplan | 266 | 500.00 | $133,000 | 4,299 | Form 4 |
| 2026-02-13 | Biller JonathanEVP and Chief Legal Officer | Saleplan | 988 | 499.00 | $493,012 | 16,838 | Form 4 |
| 2026-02-13 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 1,500 | 499.99 | $749,985 | 46,132 | Form 4 |
| 2026-02-11 | Ambrose KristenSVP & Chief Accounting Officer | Saleplan | 1,376 | 460.43 | $633,552 | 10,127 | Form 4 |
| 2026-02-11 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Saleplan | 1,751 | 460.43 | $806,213 | 22,046 | Form 4 |
| 2026-02-11 | Biller JonathanEVP and Chief Legal Officer | Saleplan | 1,925 | 460.43 | $886,328 | 20,819 | Form 4 |
| 2026-02-11 | Bunnage Mark E.EVP, Chief Scientific Officer | Saleplan | 2,021 | 460.43 | $930,529 | 12,914 | Form 4 |
| 2026-02-11 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 466 | 460.43 | $214,560 | 51,436 | Form 4 |
| 2026-01-07 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 4,500 | 474.99 | $2.14M | 42,293 | Form 4 |
| 2026-01-06 | Wagner Charles F JrEVP, CO & FO | Saleplan | 9,532 | 461.00 | $4.39M | 37,725 | Form 4 |
| 2025-12-03 | Biller JonathanEVP and Chief Legal Officer | Saleplan | 347 | 449.00 | $155,803 | 15,306 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 4,469 | 440.40 | $1.97M | 83,338 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 1,320 | 441.26 | $582,463 | 82,018 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 2,469 | 443.21 | $1.09M | 79,549 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 4,352 | 444.36 | $1.93M | 75,197 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 7,899 | 445.56 | $3.52M | 67,298 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 1,152 | 447.05 | $515,002 | 66,146 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 2,320 | 448.78 | $1.04M | 63,826 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 5,880 | 449.84 | $2.65M | 57,946 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 5,809 | 451.20 | $2.62M | 52,137 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 15,681 | 452.20 | $7.09M | 36,456 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 10,360 | 453.34 | $4.70M | 26,096 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 2,070 | 455.22 | $942,305 | 24,026 | Form 4 |
| 2025-12-03 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 4,500 | 449.99 | $2.02M | 46,793 | Form 4 |
| 2025-12-03 | Wagner Charles F JrEVP, CO & FO | Saleplan | 7,000 | 451.00 | $3.16M | 44,725 | Form 4 |
| 2025-12-03 | Wagner Charles F JrEVP, CO & FO | Saleplan | 7,000 | 461.00 | $3.23M | 37,725 | Form 4 |
| 2025-11-17 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Saleplan | 2,500 | 434.58 | $1.09M | 16,852 | Form 4 |
| 2025-11-14 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 32,234 | 440.30 | $14.19M | 45,396 | Form 4 |
| 2025-11-14 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 21,330 | 441.35 | $9.41M | 24,066 | Form 4 |
| 2025-11-14 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 40 | 442.00 | $17,680 | 24,026 | Form 4 |
| 2025-11-13 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 18,528 | 440.22 | $8.16M | 25,186 | Form 4 |
| 2025-11-13 | Leiden Jeffrey MDirector, Executive Chairman | Saleplan | 1,160 | 441.05 | $511,618 | 24,026 | Form 4 |
| 2025-10-02 | Biller JonathanEVP and Chief Legal Officer | Saleplan | 694 | 404.21 | $280,522 | 15,653 | Form 4 |
| 2025-08-27 | Bhatia Sangeeta N.Director | Saleplan | 266 | 386.69 | $102,860 | 4,565 | Form 4 |
| 2025-08-06 | Sachs Bruce IDirector | Buy | 1,634 | 389.36 | $636,214 | 41,634 | Form 4 |
| 2025-08-06 | Sachs Bruce IDirector | Buy | 3,366 | 389.84 | $1.31M | 45,000 | Form 4 |
| 2025-08-06 | Kewalramani ReshmaDirector, CEO & President | Buy | 4,290 | 389.08 | $1.67M | 110,258 | Form 4 |
| 2025-08-06 | Kewalramani ReshmaDirector, CEO & President | Buy | 5,710 | 389.95 | $2.23M | 115,968 | Form 4 |
| 2025-05-15 | Altshuler DavidEVP, Chief Scientific Officer | Saleplan | 52 | 424.69 | $22,084 | 23,281 | Form 4 |
| 2025-05-02 | Bhatia Sangeeta N.Director | Saleplan | 400 | 505.86 | $202,344 | 4,831 | Form 4 |
| 2025-03-13 | Altshuler DavidEVP, Chief Scientific Officer | Saleplan | 3,231 | 510.00 | $1.65M | 23,281 | Form 4 |
| 2025-03-10 | Altshuler DavidEVP, Chief Scientific Officer | Saleplan | 3,231 | 500.00 | $1.62M | 26,512 | Form 4 |
| 2025-03-10 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 3,242 | 499.99 | $1.62M | 51,239 | Form 4 |
| 2025-03-10 | Wagner Charles F JrEVP & Chief Financial Officer | Saleplan | 3,298 | 500.00 | $1.65M | 51,671 | Form 4 |
| 2025-03-04 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 4,058 | 485.49 | $1.97M | 54,481 | Form 4 |
| 2025-03-03 | Altshuler DavidEVP, Chief Scientific Officer | Saleplan | 3,231 | 490.00 | $1.58M | 29,743 | Form 4 |
| 2025-02-27 | Altshuler DavidEVP, Chief Scientific Officer | Saleplan | 1,272 | 480.00 | $610,560 | 32,974 | Form 4 |
| 2025-02-27 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Saleplan | 2,650 | 475.34 | $1.26M | 19,352 | Form 4 |
| 2025-02-27 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 530 | 475.34 | $251,930 | 58,539 | Form 4 |
| 2025-02-25 | Altshuler DavidEVP, Chief Scientific Officer | Saleplan | 848 | 480.95 | $407,846 | 40,200 | Form 4 |
| 2025-02-25 | Ambrose KristenSVP & Chief Accounting Officer | Saleplan | 884 | 480.95 | $425,160 | 9,086 | Form 4 |
| 2025-02-25 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Saleplan | 1,767 | 480.95 | $849,839 | 24,484 | Form 4 |
| 2025-02-25 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 354 | 480.95 | $170,256 | 64,031 | Form 4 |
| 2025-02-20 | Altshuler DavidEVP, Chief Scientific Officer | Saleplan | 1,111 | 480.00 | $533,280 | 45,019 | Form 4 |
| 2025-02-18 | Ambrose KristenSVP & Chief Accounting Officer | Saleplan | 671 | 455.06 | $305,345 | 10,798 | Form 4 |
| 2025-02-18 | Biller JonathanEVP and Chief Legal Officer | Saleplan | 1,657 | 455.06 | $754,034 | 17,606 | Form 4 |
| 2025-02-18 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 244 | 455.06 | $111,035 | 67,695 | Form 4 |
| 2025-02-11 | Ambrose KristenSVP & Chief Accounting Officer | Saleplan | 1,376 | 459.83 | $632,726 | 9,953 | Form 4 |
| 2025-02-11 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Saleplan | 1,747 | 459.83 | $803,323 | 23,225 | Form 4 |
| 2025-02-11 | Biller JonathanEVP and Chief Legal Officer | Saleplan | 3,433 | 459.87 | $1.58M | 16,330 | Form 4 |
| 2025-02-11 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Saleplan | 310 | 459.83 | $142,547 | 64,021 | Form 4 |
| 2024-11-15 | Altshuler DavidEVP, Chief Scientific Officer | Saleplan | 15 | 478.56 | $7,178 | 25,813 | Form 4 |
| 2024-11-11 | Wagner Charles F JrEVP & Chief Financial Officer | Saleplan | 3,000 | 518.27 | $1.55M | 44,137 | Form 4 |
| 2024-11-08 | Kewalramani ReshmaDirector, CEO & President | Saleplan | 15,198 | 515.00 | $7.83M | 75,772 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
84 × shares withheld for tax80 × grant or award8 × option exercise6 × returned to the company2 × gift
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-08 | van Grunsven JasperEVP, CP and NPPO | Grant or award A | +8,682 | – | 8,682 | Form 4 |
| 2026-08-28 | Ambrose KristenSVP & Chief Accounting Officer | Grant or award A | +5,000 | – | 11,624 | Form 4 |
| 2026-08-27 | Sachs Bruce IDirector | Gift G | −6,000 | – | 39,000 | Form 4 |
| 2026-07-21 | Sachdev AmitEVP Chief Patient & Ext Af Off | Grant or award A | +8,251 | – | 66,512 | Form 4 |
| 2026-07-21 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Grant or award A | +8,251 | – | 53,572 | Form 4 |
| 2026-05-01 | Bhatia Sangeeta N.Director | Grant or award A | +943 | – | 5,242 | Form 4 |
| 2026-05-01 | Garber Alan MDirector | Grant or award A | +472 | – | 7,344 | Form 4 |
| 2026-05-01 | McKenzie DianaDirector | Grant or award A | +943 | – | 3,174 | Form 4 |
| 2026-05-01 | McKenzie DianaDirector | Returned to the company D | −796 | – | 2,378 | Form 4 |
| 2026-05-01 | Schneider JenniferDirector | Grant or award A | +472 | – | 2,190 | Form 4 |
| 2026-05-01 | Schneider JenniferDirector | Returned to the company D | −796 | – | 1,394 | Form 4 |
| 2026-05-01 | Thornberry NancyDirector | Grant or award A | +472 | – | 2,507 | Form 4 |
| 2026-05-01 | Thornberry NancyDirector | Returned to the company D | −398 | – | 2,109 | Form 4 |
| 2026-05-01 | Upadhyay SuketuDirector | Returned to the company D | −796 | – | 1,558 | Form 4 |
| 2026-02-24 | Ambrose KristenSVP & Chief Accounting Officer | Shares withheld for tax F | −546 | 485.11 | 7,204 | Form 4 |
| 2026-02-24 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Shares withheld for tax F | −1,627 | 485.11 | 19,100 | Form 4 |
| 2026-02-24 | Biller JonathanEVP and Chief Legal Officer | Shares withheld for tax F | −1,144 | 485.11 | 14,604 | Form 4 |
| 2026-02-24 | Bozic CarmenEVP and CMO | Shares withheld for tax F | −1,453 | 485.11 | 40,063 | Form 4 |
| 2026-02-24 | Bunnage Mark E.EVP, Chief Scientific Officer | Shares withheld for tax F | −582 | 485.11 | 7,904 | Form 4 |
| 2026-02-24 | Kewalramani ReshmaDirector, CEO & President | Shares withheld for tax F | −4,981 | 485.11 | 138,278 | Form 4 |
| 2026-02-24 | McKechnie DuncanEVP, Chief Commercial Officer | Shares withheld for tax F | −873 | 485.11 | 22,469 | Form 4 |
| 2026-02-24 | Sachdev AmitEVP Chief Patient & Ext Af Off | Shares withheld for tax F | −1,518 | 485.11 | 57,416 | Form 4 |
| 2026-02-24 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Shares withheld for tax F | −1,627 | 485.11 | 47,023 | Form 4 |
| 2026-02-24 | Wagner Charles F JrEVP, CO & FO | Shares withheld for tax F | −1,744 | 485.11 | 47,042 | Form 4 |
| 2026-02-24 | Leiden Jeffrey MDirector, Executive Chairman | Shares withheld for tax F | −3,547 | 485.11 | 34,797 | Form 4 |
| 2026-02-19 | Sachdev AmitEVP Chief Patient & Ext Af Off | Option exercise M | +23,479 | 155.57 | 92,521 | Form 4 |
| 2026-02-19 | Sachdev AmitEVP Chief Patient & Ext Af Off | Option exercise M | +25,026 | 187.53 | 117,547 | Form 4 |
| 2026-02-18 | Leiden Jeffrey MDirector, Executive Chairman | Shares withheld for tax F | −2,964 | 483.75 | 38,344 | Form 4 |
| 2026-02-17 | Ambrose KristenSVP & Chief Accounting Officer | Grant or award A | +1,809 | – | 10,543 | Form 4 |
| 2026-02-17 | Ambrose KristenSVP & Chief Accounting Officer | Shares withheld for tax F | −598 | 483.75 | 9,945 | Form 4 |
| 2026-02-17 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Grant or award A | +4,962 | – | 25,105 | Form 4 |
| 2026-02-17 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Shares withheld for tax F | −1,530 | 483.75 | 23,575 | Form 4 |
| 2026-02-17 | Biller JonathanEVP and Chief Legal Officer | Grant or award A | +4,135 | – | 20,973 | Form 4 |
| 2026-02-17 | Biller JonathanEVP and Chief Legal Officer | Shares withheld for tax F | −1,505 | 483.75 | 19,468 | Form 4 |
| 2026-02-17 | Bozic CarmenEVP and CMO | Grant or award A | +5,375 | – | 43,428 | Form 4 |
| 2026-02-17 | Bozic CarmenEVP and CMO | Shares withheld for tax F | −1,912 | 483.75 | 41,516 | Form 4 |
| 2026-02-17 | Bunnage Mark E.EVP, Chief Scientific Officer | Grant or award A | +2,584 | – | 13,215 | Form 4 |
| 2026-02-17 | Bunnage Mark E.EVP, Chief Scientific Officer | Shares withheld for tax F | −1,110 | 483.75 | 12,105 | Form 4 |
| 2026-02-17 | Kewalramani ReshmaDirector, CEO & President | Grant or award A | +16,326 | – | 149,813 | Form 4 |
| 2026-02-17 | Kewalramani ReshmaDirector, CEO & President | Shares withheld for tax F | −6,554 | 483.75 | 143,259 | Form 4 |
| 2026-02-17 | Leiden Jeffrey MDirector, Executive Chairman | Grant or award A | +8,269 | – | 41,308 | Form 4 |
| 2026-02-17 | McKechnie DuncanEVP, Chief Commercial Officer | Grant or award A | +4,962 | – | 24,490 | Form 4 |
| 2026-02-17 | McKechnie DuncanEVP, Chief Commercial Officer | Shares withheld for tax F | −1,148 | 483.75 | 23,342 | Form 4 |
| 2026-02-17 | Sachdev AmitEVP Chief Patient & Ext Af Off | Grant or award A | +5,789 | – | 71,182 | Form 4 |
| 2026-02-17 | Sachdev AmitEVP Chief Patient & Ext Af Off | Shares withheld for tax F | −2,140 | 483.75 | 69,042 | Form 4 |
| 2026-02-17 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Grant or award A | +5,789 | – | 51,921 | Form 4 |
| 2026-02-17 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Shares withheld for tax F | −2,294 | 483.75 | 49,627 | Form 4 |
| 2026-02-17 | Wagner Charles F JrEVP, CO & FO | Grant or award A | +7,365 | – | 51,080 | Form 4 |
| 2026-02-17 | Wagner Charles F JrEVP, CO & FO | Shares withheld for tax F | −2,294 | 483.75 | 48,786 | Form 4 |
| 2026-02-13 | Ambrose KristenSVP & Chief Accounting Officer | Shares withheld for tax F | −1,393 | 487.76 | 8,734 | Form 4 |
| 2026-02-13 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Shares withheld for tax F | −1,903 | 487.76 | 20,143 | Form 4 |
| 2026-02-13 | Biller JonathanEVP and Chief Legal Officer | Shares withheld for tax F | −2,993 | 487.76 | 17,826 | Form 4 |
| 2026-02-13 | Bozic CarmenEVP and CMO | Shares withheld for tax F | −3,804 | 487.76 | 38,053 | Form 4 |
| 2026-02-13 | Bunnage Mark E.EVP, Chief Scientific Officer | Shares withheld for tax F | −2,283 | 487.76 | 10,631 | Form 4 |
| 2026-02-13 | Kewalramani ReshmaDirector, CEO & President | Shares withheld for tax F | −13,041 | 487.76 | 133,487 | Form 4 |
| 2026-02-13 | McKechnie DuncanEVP, Chief Commercial Officer | Shares withheld for tax F | −2,283 | 487.76 | 19,528 | Form 4 |
| 2026-02-13 | Sachdev AmitEVP Chief Patient & Ext Af Off | Shares withheld for tax F | −3,548 | 487.76 | 65,393 | Form 4 |
| 2026-02-13 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Shares withheld for tax F | −3,804 | 487.76 | 47,632 | Form 4 |
| 2026-02-13 | Wagner Charles F JrEVP, CO & FO | Shares withheld for tax F | −4,565 | 487.76 | 43,715 | Form 4 |
| 2026-02-10 | Ambrose KristenSVP & Chief Accounting Officer | Shares withheld for tax F | −592 | 468.41 | 11,503 | Form 4 |
| 2026-02-10 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Shares withheld for tax F | −872 | 468.41 | 23,797 | Form 4 |
| 2026-02-10 | Biller JonathanEVP and Chief Legal Officer | Shares withheld for tax F | −1,630 | 468.41 | 22,744 | Form 4 |
| 2026-02-10 | Bozic CarmenEVP and CMO | Shares withheld for tax F | −2,145 | 468.41 | 41,857 | Form 4 |
| 2026-02-10 | Bunnage Mark E.EVP, Chief Scientific Officer | Shares withheld for tax F | −1,127 | 468.41 | 14,935 | Form 4 |
| 2026-02-10 | Kewalramani ReshmaDirector, CEO & President | Shares withheld for tax F | −8,297 | 468.41 | 146,528 | Form 4 |
| 2026-02-10 | McKechnie DuncanEVP, Chief Commercial Officer | Shares withheld for tax F | −1,127 | 468.41 | 21,811 | Form 4 |
| 2026-02-10 | Sachdev AmitEVP Chief Patient & Ext Af Off | Shares withheld for tax F | −2,057 | 468.41 | 68,941 | Form 4 |
| 2026-02-10 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Shares withheld for tax F | −2,140 | 468.41 | 51,902 | Form 4 |
| 2026-02-10 | Wagner Charles F JrEVP, CO & FO | Shares withheld for tax F | −3,045 | 468.41 | 48,280 | Form 4 |
| 2026-01-22 | Altshuler DavidEVP, Chief Scientific Officer | Grant or award A | +7,866 | – | 31,149 | Form 4 |
| 2026-01-22 | Altshuler DavidEVP, Chief Scientific Officer | Grant or award A | +3,328 | – | 34,477 | Form 4 |
| 2026-01-22 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Grant or award A | +3,934 | – | 20,786 | Form 4 |
| 2026-01-22 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Grant or award A | +3,883 | – | 24,669 | Form 4 |
| 2026-01-22 | Biller JonathanEVP and Chief Legal Officer | Grant or award A | +6,294 | – | 21,600 | Form 4 |
| 2026-01-22 | Biller JonathanEVP and Chief Legal Officer | Grant or award A | +2,774 | – | 24,374 | Form 4 |
| 2026-01-22 | Bozic CarmenEVP and CMO | Grant or award A | +7,866 | – | 40,535 | Form 4 |
| 2026-01-22 | Bozic CarmenEVP and CMO | Grant or award A | +3,467 | – | 44,002 | Form 4 |
| 2026-01-22 | Kewalramani ReshmaDirector, CEO & President | Grant or award A | +26,972 | – | 142,940 | Form 4 |
| 2026-01-22 | Kewalramani ReshmaDirector, CEO & President | Grant or award A | +11,885 | – | 154,825 | Form 4 |
| 2026-01-22 | Leiden Jeffrey MDirector, Executive Chairman | Grant or award A | +9,012 | – | 33,039 | Form 4 |
| 2026-01-22 | McKechnie DuncanEVP, Chief Commercial Officer | Grant or award A | +4,720 | – | 20,858 | Form 4 |
| 2026-01-22 | McKechnie DuncanEVP, Chief Commercial Officer | Grant or award A | +2,080 | – | 22,938 | Form 4 |
| 2026-01-22 | Sachdev AmitEVP Chief Patient & Ext Af Off | Grant or award A | +7,866 | – | 67,115 | Form 4 |
| 2026-01-22 | Sachdev AmitEVP Chief Patient & Ext Af Off | Grant or award A | +3,883 | – | 70,998 | Form 4 |
| 2026-01-22 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Grant or award A | +7,866 | – | 50,159 | Form 4 |
| 2026-01-22 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Grant or award A | +3,883 | – | 54,042 | Form 4 |
| 2026-01-22 | Wagner Charles F JrEVP, CO & FO | Grant or award A | +9,440 | – | 47,165 | Form 4 |
| 2026-01-22 | Wagner Charles F JrEVP, CO & FO | Grant or award A | +4,160 | – | 51,325 | Form 4 |
| 2026-01-22 | Ambrose KristenSVP & Chief Accounting Officer | Grant or award A | +2,950 | – | 10,795 | Form 4 |
| 2026-01-22 | Ambrose KristenSVP & Chief Accounting Officer | Grant or award A | +1,300 | – | 12,095 | Form 4 |
| 2026-01-06 | Wagner Charles F JrEVP, CO & FO | Option exercise M | +9,532 | 189.38 | 47,257 | Form 4 |
| 2025-12-04 | Leiden Jeffrey MDirector, Executive Chairman | Option exercise M | +1 | 91.05 | 24,027 | Form 4 |
| 2025-12-03 | Leiden Jeffrey MDirector, Executive Chairman | Option exercise M | +63,781 | 86.52 | 87,807 | Form 4 |
| 2025-11-19 | Carney LloydDirector | Gift G | −800 | – | 6,315 | Form 4 |
| 2025-11-14 | Leiden Jeffrey MDirector, Executive Chairman | Option exercise M | +13,835 | 91.05 | 37,861 | Form 4 |
| 2025-11-14 | Leiden Jeffrey MDirector, Executive Chairman | Option exercise M | +39,769 | 86.52 | 77,630 | Form 4 |
| 2025-11-13 | Leiden Jeffrey MDirector, Executive Chairman | Option exercise M | +19,688 | 91.05 | 43,714 | Form 4 |
| 2025-10-01 | Biller JonathanEVP and Chief Legal Officer | Shares withheld for tax F | −1,259 | 400.00 | 16,347 | Form 4 |
| 2025-07-01 | Arbuckle Stuart AEVP, COO | Shares withheld for tax F | −37,243 | 450.23 | 63,368 | Form 4 |
| 2025-05-13 | Arbuckle Stuart AEVP, COO | Grant or award A | +37,622 | – | 100,611 | Form 4 |
| 2025-05-01 | Bhatia Sangeeta N.Director | Grant or award A | +796 | – | 5,231 | Form 4 |
| 2025-05-01 | Carney LloydDirector | Grant or award A | +796 | – | 7,115 | Form 4 |
| 2025-05-01 | Garber Alan MDirector | Grant or award A | +398 | – | 6,872 | Form 4 |
| 2025-05-01 | McKenzie DianaDirector | Grant or award A | +796 | – | 3,232 | Form 4 |
| 2025-05-01 | McKenzie DianaDirector | Returned to the company D | −1,001 | – | 2,231 | Form 4 |
| 2025-05-01 | Schneider JenniferDirector | Grant or award A | +796 | – | 1,718 | Form 4 |
| 2025-05-01 | Thornberry NancyDirector | Grant or award A | +398 | – | 2,035 | Form 4 |
| 2025-05-01 | Upadhyay SuketuDirector | Grant or award A | +796 | – | 3,355 | Form 4 |
| 2025-05-01 | Upadhyay SuketuDirector | Returned to the company D | −1,001 | – | 2,354 | Form 4 |
| 2025-02-26 | Altshuler DavidEVP, Chief Scientific Officer | Shares withheld for tax F | −5,954 | 479.61 | 34,246 | Form 4 |
| 2025-02-26 | Ambrose KristenSVP & Chief Accounting Officer | Shares withheld for tax F | −1,241 | 479.61 | 7,845 | Form 4 |
| 2025-02-26 | Arbuckle Stuart AEVP, COO | Shares withheld for tax F | −7,071 | 479.61 | 62,935 | Form 4 |
| 2025-02-26 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Shares withheld for tax F | −2,482 | 479.61 | 22,002 | Form 4 |
| 2025-02-26 | Bozic CarmenEVP and CMO | Shares withheld for tax F | −4,962 | 479.61 | 32,669 | Form 4 |
| 2025-02-26 | Kewalramani ReshmaDirector, CEO & President | Shares withheld for tax F | −14,079 | 479.61 | 105,915 | Form 4 |
| 2025-02-26 | Sachdev AmitEVP Chief Patient & Ext Af Off | Shares withheld for tax F | −3,703 | 479.61 | 68,490 | Form 4 |
| 2025-02-26 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Shares withheld for tax F | −4,962 | 479.61 | 59,069 | Form 4 |
| 2025-02-26 | Wagner Charles F JrEVP & Chief Financial Officer | Shares withheld for tax F | −4,962 | 479.61 | 54,969 | Form 4 |
| 2025-02-24 | Altshuler DavidEVP, Chief Scientific Officer | Shares withheld for tax F | −3,971 | 483.28 | 41,048 | Form 4 |
| 2025-02-24 | Ambrose KristenSVP & Chief Accounting Officer | Shares withheld for tax F | −828 | 483.28 | 9,970 | Form 4 |
| 2025-02-24 | Arbuckle Stuart AEVP, COO | Shares withheld for tax F | −4,716 | 483.28 | 70,006 | Form 4 |
| 2025-02-24 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Shares withheld for tax F | −1,656 | 483.28 | 26,251 | Form 4 |
| 2025-02-24 | Bozic CarmenEVP and CMO | Shares withheld for tax F | −3,310 | 483.28 | 37,631 | Form 4 |
| 2025-02-24 | Kewalramani ReshmaDirector, CEO & President | Shares withheld for tax F | −9,386 | 483.28 | 119,994 | Form 4 |
| 2025-02-24 | Sachdev AmitEVP Chief Patient & Ext Af Off | Shares withheld for tax F | −2,470 | 483.28 | 72,193 | Form 4 |
| 2025-02-24 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Shares withheld for tax F | −3,310 | 483.28 | 64,385 | Form 4 |
| 2025-02-24 | Wagner Charles F JrEVP & Chief Financial Officer | Shares withheld for tax F | −3,310 | 483.28 | 59,931 | Form 4 |
| 2025-02-14 | Altshuler DavidEVP, Chief Scientific Officer | Shares withheld for tax F | −2,293 | 463.46 | 46,130 | Form 4 |
| 2025-02-14 | Ambrose KristenSVP & Chief Accounting Officer | Shares withheld for tax F | −564 | 463.46 | 11,469 | Form 4 |
| 2025-02-14 | Arbuckle Stuart AEVP, COO | Shares withheld for tax F | −2,724 | 463.46 | 74,722 | Form 4 |
| 2025-02-14 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Shares withheld for tax F | −1,529 | 463.46 | 27,907 | Form 4 |
| 2025-02-14 | Biller JonathanEVP and Chief Legal Officer | Shares withheld for tax F | −1,504 | 463.46 | 19,263 | Form 4 |
| 2025-02-14 | Bozic CarmenEVP and CMO | Shares withheld for tax F | −1,912 | 463.46 | 40,941 | Form 4 |
| 2025-02-14 | Kewalramani ReshmaDirector, CEO & President | Shares withheld for tax F | −6,553 | 463.46 | 129,380 | Form 4 |
| 2025-02-14 | Leiden Jeffrey MDirector, Executive Chairman | Shares withheld for tax F | −6,066 | 463.46 | 24,026 | Form 4 |
| 2025-02-14 | Sachdev AmitEVP Chief Patient & Ext Af Off | Shares withheld for tax F | −2,139 | 463.46 | 74,663 | Form 4 |
| 2025-02-14 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Shares withheld for tax F | −2,293 | 463.46 | 67,939 | Form 4 |
| 2025-02-14 | Wagner Charles F JrEVP & Chief Financial Officer | Shares withheld for tax F | −2,293 | 463.46 | 63,241 | Form 4 |
| 2025-02-13 | Leiden Jeffrey MDirector, Executive Chairman | Shares withheld for tax F | −2,525 | 450.83 | 30,092 | Form 4 |
| 2025-02-12 | Altshuler DavidEVP, Chief Scientific Officer | Grant or award A | +5,324 | – | 48,423 | Form 4 |
| 2025-02-12 | Ambrose KristenSVP & Chief Accounting Officer | Grant or award A | +2,080 | – | 12,033 | Form 4 |
| 2025-02-12 | Arbuckle Stuart AEVP, COO | Grant or award A | +7,903 | – | 77,446 | Form 4 |
| 2025-02-12 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Grant or award A | +6,211 | – | 29,436 | Form 4 |
| 2025-02-12 | Biller JonathanEVP and Chief Legal Officer | Grant or award A | +4,437 | – | 20,767 | Form 4 |
| 2025-02-12 | Bozic CarmenEVP and CMO | Grant or award A | +5,546 | – | 42,853 | Form 4 |
| 2025-02-12 | Kewalramani ReshmaDirector, CEO & President | Grant or award A | +19,015 | – | 135,933 | Form 4 |
| 2025-02-12 | Sachdev AmitEVP Chief Patient & Ext Af Off | Grant or award A | +6,211 | – | 76,802 | Form 4 |
| 2025-02-12 | Leiden Jeffrey MDirector, Executive Chairman | Grant or award A | +7,209 | – | 32,617 | Form 4 |
| 2025-02-12 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Grant or award A | +6,211 | – | 70,232 | Form 4 |
| 2025-02-12 | Wagner Charles F JrEVP & Chief Financial Officer | Grant or award A | +6,655 | – | 65,534 | Form 4 |
| 2025-02-10 | Altshuler DavidEVP, Chief Scientific Officer | Shares withheld for tax F | −2,142 | 467.98 | 43,099 | Form 4 |
| 2025-02-10 | Ambrose KristenSVP & Chief Accounting Officer | Shares withheld for tax F | −591 | 467.98 | 11,329 | Form 4 |
| 2025-02-10 | Arbuckle Stuart AEVP, COO | Shares withheld for tax F | −3,220 | 467.98 | 69,543 | Form 4 |
| 2025-02-10 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Shares withheld for tax F | −876 | 467.98 | 24,972 | Form 4 |
| 2025-02-10 | Biller JonathanEVP and Chief Legal Officer | Shares withheld for tax F | −1,632 | 467.98 | 19,763 | Form 4 |
| 2025-02-10 | Bozic CarmenEVP and CMO | Shares withheld for tax F | −2,142 | 467.98 | 37,307 | Form 4 |
| 2025-02-10 | Kewalramani ReshmaDirector, CEO & President | Shares withheld for tax F | −8,300 | 467.98 | 116,918 | Form 4 |
| 2025-02-10 | Sachdev AmitEVP Chief Patient & Ext Af Off | Shares withheld for tax F | −2,056 | 467.98 | 70,591 | Form 4 |
| 2025-02-10 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Shares withheld for tax F | −2,143 | 467.98 | 64,331 | Form 4 |
| 2025-02-10 | Wagner Charles F JrEVP & Chief Financial Officer | Shares withheld for tax F | −2,649 | 467.98 | 58,879 | Form 4 |
| 2025-02-04 | Altshuler DavidEVP, Chief Scientific Officer | Grant or award A | +12,314 | – | 38,127 | Form 4 |
| 2025-02-04 | Altshuler DavidEVP, Chief Scientific Officer | Grant or award A | +7,114 | – | 45,241 | Form 4 |
| 2025-02-04 | Ambrose KristenSVP & Chief Accounting Officer | Grant or award A | +2,566 | – | 10,066 | Form 4 |
| 2025-02-04 | Ambrose KristenSVP & Chief Accounting Officer | Grant or award A | +1,854 | – | 11,920 | Form 4 |
| 2025-02-04 | Arbuckle Stuart AEVP, COO | Grant or award A | +14,624 | – | 64,315 | Form 4 |
| 2025-02-04 | Arbuckle Stuart AEVP, COO | Grant or award A | +8,448 | – | 72,763 | Form 4 |
| 2025-02-04 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Grant or award A | +5,132 | – | 21,104 | Form 4 |
| 2025-02-04 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | Grant or award A | +4,744 | – | 25,848 | Form 4 |
| 2025-02-04 | Biller JonathanEVP and Chief Legal Officer | Grant or award A | +4,744 | – | 21,395 | Form 4 |
| 2025-02-04 | Bozic CarmenEVP and CMO | Grant or award A | +10,262 | – | 33,521 | Form 4 |
| 2025-02-04 | Bozic CarmenEVP and CMO | Grant or award A | +5,928 | – | 39,449 | Form 4 |
| 2025-02-04 | Kewalramani ReshmaDirector, CEO & President | Grant or award A | +29,118 | – | 104,890 | Form 4 |
| 2025-02-04 | Kewalramani ReshmaDirector, CEO & President | Grant or award A | +20,328 | – | 125,218 | Form 4 |
| 2025-02-04 | Leiden Jeffrey MDirector, Executive Chairman | Grant or award A | +15,414 | – | 25,408 | Form 4 |
| 2025-02-04 | Sachdev AmitEVP Chief Patient & Ext Af Off | Grant or award A | +8,210 | – | 65,533 | Form 4 |
| 2025-02-04 | Sachdev AmitEVP Chief Patient & Ext Af Off | Grant or award A | +7,114 | – | 72,647 | Form 4 |
| 2025-02-04 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Grant or award A | +10,262 | – | 59,360 | Form 4 |
| 2025-02-04 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Grant or award A | +7,114 | – | 66,474 | Form 4 |
| 2025-02-04 | Wagner Charles F JrEVP & Chief Financial Officer | Grant or award A | +10,262 | – | 54,414 | Form 4 |
| 2025-02-04 | Wagner Charles F JrEVP & Chief Financial Officer | Grant or award A | +7,114 | – | 61,528 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.